----item----
version: 1
id: {55889777-47ED-4458-9A9F-444E9F2C31E7}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/07/13/Big pharmas future panel discussion
parent: {21855792-BFDE-4296-989C-646D68C6D7F2}
name: Big pharmas future panel discussion
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 801f1c33-c5a6-4435-9d79-a0cacc80ded7

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 40

 Big pharma's future: panel discussion  
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 35

Big pharmas future panel discussion
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1965

<p> Big pharma companies are expected to turn a corner in 2016, when the decline in prescription drug revenues should stem, with a return to annual growth then forecast. This is the finding of a new report, The Outlook for Big Pharma, published by Datamonitor Healthcare, in which revenues from a group of 16 top big pharma companies are forecast to grow from $439bn in 2014 to $499bn in 2024. </p> <p> In a panel discussion chaired by Mike Ward, global director of content for Informa Pharma Insights, the findings of the report are dissected and debated. Joining Mike are panelists </p> <p> * Ali Al-Bazergan, Datamonitor Healthcare senior company analyst and author of the report; </p> <p> * Eleanor Malone, editor of Scrip Intelligence editor; and </p> <p> * Armando Uribe, financial analyst for BioMedTracker. </p> <p> In the first part, the panelists consider the outlook for big pharma: </p> <p> <preform><iframe src="https://player.vimeo.com/video/133636329" frameborder="0" webkitallowfullscreen="" mozallowfullscreen="" allowfullscreen=""></iframe> <p> In the second part, the panelists discuss who the winners and losers are likely to be: </p> <iframe src="https://player.vimeo.com/video/133636330" frameborder="0" webkitallowfullscreen="" mozallowfullscreen="" allowfullscreen=""></iframe> <p> In the third part, the panelists explore the threats and opportunities facing big pharma over the next 10 years: </p> <iframe src="https://player.vimeo.com/video/133637717" frameborder="0" webkitallowfullscreen="" mozallowfullscreen="" allowfullscreen=""></iframe> </preform></p> <p><p> <h2> Related reading: </h2> <p> <a href="http://www.scripintelligence.com/home/Big-pharma-to-add-60bn-in-sales-by-2024-359453" target="_new">Big pharma to add $60bn in sales by 2024</a> </p> <p> For access to the full report from Datamonitor Healthcare, click <a href="http://www.datamonitorhealthcare.com/new-report-2015-big-pharma-outlook/" target="_new">here</a>. </p> 
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 398

<p> Big pharma companies are expected to turn a corner in 2016, when the decline in prescription drug revenues should stem, with a return to annual growth then forecast. This is the finding of a new report, The Outlook for Big Pharma, published by Datamonitor Healthcare, in which revenues from a group of 16 top big pharma companies are forecast to grow from $439bn in 2014 to $499bn in 2024. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 35

Big pharmas future panel discussion
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150713T195837
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150713T195837
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150713T195837
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029263
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 40

 Big pharma's future: panel discussion  
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359412
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042424Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

801f1c33-c5a6-4435-9d79-a0cacc80ded7
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042424Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
